ES2907008T3 - Compuestos de heteroarilo sustituidos con fosfinóxido alquilamida como moduladores de respuestas de IL-12, IL-23 y/o IFN alfa - Google Patents

Compuestos de heteroarilo sustituidos con fosfinóxido alquilamida como moduladores de respuestas de IL-12, IL-23 y/o IFN alfa Download PDF

Info

Publication number
ES2907008T3
ES2907008T3 ES17822919T ES17822919T ES2907008T3 ES 2907008 T3 ES2907008 T3 ES 2907008T3 ES 17822919 T ES17822919 T ES 17822919T ES 17822919 T ES17822919 T ES 17822919T ES 2907008 T3 ES2907008 T3 ES 2907008T3
Authority
ES
Spain
Prior art keywords
alkyl
aryl
cycloalkyl
substituted
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES17822919T
Other languages
English (en)
Spanish (es)
Inventor
Michael G Yang
Zili Xiao
John V Duncia
David S Weinstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2907008T3 publication Critical patent/ES2907008T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650905—Six-membered rings having the nitrogen atoms in the positions 1 and 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES17822919T 2016-12-13 2017-12-12 Compuestos de heteroarilo sustituidos con fosfinóxido alquilamida como moduladores de respuestas de IL-12, IL-23 y/o IFN alfa Active ES2907008T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662433470P 2016-12-13 2016-12-13
PCT/US2017/065665 WO2018111787A1 (en) 2016-12-13 2017-12-12 Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses

Publications (1)

Publication Number Publication Date
ES2907008T3 true ES2907008T3 (es) 2022-04-21

Family

ID=60888685

Family Applications (1)

Application Number Title Priority Date Filing Date
ES17822919T Active ES2907008T3 (es) 2016-12-13 2017-12-12 Compuestos de heteroarilo sustituidos con fosfinóxido alquilamida como moduladores de respuestas de IL-12, IL-23 y/o IFN alfa

Country Status (10)

Country Link
US (1) US10294256B2 (enExample)
EP (1) EP3555111B1 (enExample)
JP (1) JP7046092B2 (enExample)
KR (1) KR102602558B1 (enExample)
CN (1) CN110267964B (enExample)
AR (1) AR110351A1 (enExample)
ES (1) ES2907008T3 (enExample)
MA (1) MA48602A (enExample)
TW (1) TW201827423A (enExample)
WO (1) WO2018111787A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY202167A (en) 2017-11-21 2024-04-12 Bristol Myers Squibb Co Sulfone pyridine alkyl amide-substituted heteroaryl compounds
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶２介導的傳訊之抑制劑
JP7485609B2 (ja) * 2018-03-22 2024-05-16 ブリストル－マイヤーズ スクイブ カンパニー ＩＬ－１２、ＩＬ－２３および／またはＩＦＮα応答のモジュレーターとして有用なピリジン含有ヘテロ環式化合物
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
CN114787154A (zh) * 2020-01-19 2022-07-22 苏州科睿思制药有限公司 一种Deucravacitinib的晶型及其制备方法和用途
CN122520625A (zh) 2020-12-22 2026-08-07 益方生物科技(上海)股份有限公司 杂芳基化合物及其制备方法和用途
CN114805438A (zh) * 2021-01-18 2022-07-29 正大天晴药业集团股份有限公司 含磷酰基的tyk2抑制剂化合物
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
CN115724830A (zh) * 2021-08-31 2023-03-03 浙江文达医药科技有限公司 作为tyk2/jak1假激酶结构域(jh2)抑制剂的化合物及合成和使用方法
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN117263913A (zh) 2022-06-20 2023-12-22 益方生物科技(上海)股份有限公司 杂芳基化合物、固体形式、制备方法及其用途
CN117362343A (zh) * 2022-07-08 2024-01-09 爱科诺生物医药(香港)有限公司 具有选择性抑制tyk2/jak1活性的化合物，包含其的药物组合物，及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270730A1 (en) * 2003-08-07 2006-11-30 Andreas Katopodis Histone deacetylase inhibitors as immunosuppressants
JP2011523646A (ja) * 2008-05-21 2011-08-18 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのリン誘導体
TW201100441A (en) * 2009-06-01 2011-01-01 Osi Pharm Inc Amino pyrimidine anticancer compounds
CN104125947A (zh) * 2011-12-21 2014-10-29 生物区欧洲有限公司 杂环脲化合物
JP6469567B2 (ja) * 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
EP2922841B8 (en) * 2012-11-08 2017-08-02 Bristol-Myers Squibb Company Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
HRP20220766T1 (hr) 2012-11-08 2022-09-16 Bristol-Myers Squibb Company Amidom-supstituirani heterociklički spojevi korisni kao modulatori il-12, il-23 i/ili ifn alfa odgovora
WO2014181287A1 (en) * 2013-05-09 2014-11-13 Piramal Enterprises Limited Heterocyclyl compounds and uses thereof
AR094537A1 (es) * 2013-11-07 2015-08-12 Bristol Myers Squibb Co COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
EP2947460A1 (en) * 2014-05-22 2015-11-25 Medizinische Universität Wien Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists

Also Published As

Publication number Publication date
KR102602558B1 (ko) 2023-11-14
US20180162889A1 (en) 2018-06-14
CN110267964A (zh) 2019-09-20
EP3555111A1 (en) 2019-10-23
AR110351A1 (es) 2019-03-20
TW201827423A (zh) 2018-08-01
EP3555111B1 (en) 2022-01-26
KR20190091536A (ko) 2019-08-06
MA48602A (fr) 2020-03-18
WO2018111787A1 (en) 2018-06-21
US10294256B2 (en) 2019-05-21
JP2020502268A (ja) 2020-01-23
JP7046092B2 (ja) 2022-04-01
CN110267964B (zh) 2022-05-03

Similar Documents

Publication Publication Date Title
KR102782807B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물
EP3555111B1 (en) Phosphine oxide alkyl amide substituted heteroaryl compounds as modulators of il-12, il-23, and/or ifn alpha responses
AU2013341195B2 (en) Alkyl amide-substituted pyrimidine compounds useful in the modulation of IL-12, IL-23 and/or IFNalpha
ES3035735T3 (en) Amide-disubstituted pyridine or pyridazine compounds
ES3059456T3 (en) Substituted heterocyclic compounds
JP7012082B2 (ja) Ｉｌ－１２、ｉｌ－２３および／またはｉｆｎ－アルファのイミダゾピリダジン調節剤
BR112020009606A2 (pt) compostos heteroaril sulfona piridina alquil de amidasubstituídos
KR102477063B1 (ko) Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물
JP2024518792A (ja) 置換ヘテロ環化合物
WO2022241175A1 (en) Substituted heterocyclic compounds
EA046543B1 (ru) Амидзамещенные гетероциклические соединения